

NHS Foundation Trust

Information Governance Department

Suite 9 Buckingham Row Brick Kiln Lane Wigan WN1 1XX

Email: foi@wwl.nhs.uk Web: www.wwl.nhs.uk

Ref: FOI/2024/9404

Date Received: 17th November 2023

Response Due: 15th December 2023

Date: 30th April 2024

Dear Sir/Madam

With reference to your request for information received on 17th November 2023, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

1. How many patients were treated with the following drugs from the following departments (for any disease) from September 2023 to October 2023 inclusive?

Drug Name	DERMATOLOGY	GASTROENTEROLOGY	RHEUMATOLOGY
Adalimumab (Humira)	13	<5	35
Adalimumab (Biosimilars)	<5	172	103
Apremilast (Otezla)	<5	0	5
Bimekizumab (Bimzelx)	14	0	0
Brodalumab (Kyntheum)	0	0	0
Certolizumab Pegol (Cimzia)	<5	0	16
Deucravacitinib (Sotyktu)	0	0	0
Etanercept (Enbrel)	0	0	25
Etanercept (Biosimilars)	0	0	142
Guselkumab (Tremfya)	40	0	0
Infliximab (Remicade)	0	0	<5
Infliximab (Biosimilars)	0	55	<5
Ixekizumab (Taltz)	0	0	0
Risankizumab (Skyrizi)	27	0	0
Secukinumab (Cosentyx)	13	0	25
Tildrakizumab (Illumetri)	0	0	0

Ustekinumab (Stelara)	17	98	<5
Upadacitinib (Rinvoq)	0	12	<5
Vedolizumab (Entyvio)	0	94	<5
Filgotinib (Jyseleca)	0	<5	5
Golimumab (Simponi)	0	0	18
Mirikizumab (Omvoh)	0	0	0
Ozanimod (Zeposia)	0	0	0
Tofacitinib (Xeljanz)	<5	0	0
Abatacept (Orencia)	0	0	16
Baricitinib (Olumiant)	0	0	10
Rituximab (Mabthera/Biosimilars)	0	0	32
Sarilumab (Kevzara)	0	0	0
Tocilizumab (RoActemra/Biosimilars)	0	0	57

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and

b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

aster

Gary Masterman Deputy Chief Pharmacist

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire, SK9 5AF

Helpline number: 0303 123 111